HNSCC cells with high CD276 expression have a greater stemness capacity as well as metastatic ability, and in vivo experiments also showed that CD276 antibody monotherapy could effectively inhibit HNSCC growth and metastasis [62]. Here, CD276 is linked to head and neck squamous cell carcinoma.